Mechanism of Action

OVERVIEW

SOMATOSTATIN RECEPTOR EXPRESSION

MECHANISM OF ACTION FOR LUTATHERA

Overview

LUTATHERA Is the First FDA-Approved RLT for the Treatment of Adult Patients With SSTR-Positive GEP-NETs¹

LUTATHERA

Somatostatin Receptor Expression

GEP-NETs Overexpress SSTR Subtype 2²

of GEP-NETs have been demonstrated to express SSTRs, with 86% expressing SSTR subtype 2^2,a,b

^aBased on a study of 100 cases with clinical and pathological data selected from a prospectively built database of patients with gastroenteropancreatic endocrine tumors referred from 3 institutions.²

^bThis work was supported by grants from Novartis.

Patients with GEP-NETs with a high density of SSTR expression may be considered for targeted treatment with LUTATHERA.³

Mechanism of Action for LUTATHERA

LUTATHERA is a targeted treatment that uses radiation to damage SSTR-positive cells and neighboring cells.³

PRECISION TARGETING FOR SSTR-POSITIVE CELLS³	ENTERS THE CELLS³
LUTATHERA contains a targeting component that helps find cells with SSTRs, including GEP-NET cancer cells.	After LUTATHERA binds to the SSTRs, it enters into the cell.
Once it finds these target cells, LUTATHERA binds to the SSTRs located on the outside of the cells.	LUTATHERA delivers radiation that causes damage to the SSTR-positive cells and nearby cells.

FDA, US Food and Drug Administration; GEP-NETs, gastroenteropancreatic neuroendocrine tumors; RLT, radioligand therapy; SSA, somatostatin analog; SSTR, somatostatin receptor.

Next: Access